Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1988136 | 0.76 | LPL (0.38) | LPLLIPGP2RX7 | |
| SCHEMBL20539899 | 0.76 | LPL (0.38) | LPLLIPGP2RX7 | |
| SCHEMBL14332408 | 0.74 | LPL (0.42) | LPLLIPGP2RX7 | |
| SCHEMBL23031851 | 0.74 | LPL (0.37) | LPLLIPGP2RX7 | |
| SCHEMBL5052586 | 0.71 | LPL (0.35) | LPLLIPGUSP30P2RX7 | |
| SCHEMBL21052188 | 0.71 | LPL (0.39) | LPLLIPGP2RX7 | |
| SCHEMBL25930160 | 0.71 | SNCA (0.37) | LPLLIPGUSP30P2RX7 | |
| SCHEMBL12067269 | 0.71 | ESR2 (0.32) | — | |
| SCHEMBL13868374 | 0.70 | LPL (0.34) | LPLLIPG | |
| SCHEMBL12913293 | 0.70 | LMNA (0.33) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116234797-A | Heterocyclic inhibitors of TEAD for the treatment of cancer | 基因泰克公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4185386-A1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054741-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | LPL 1208/4885LIPG 785/4885USP30 3602/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | LPL 1208/4885LIPG 785/4885USP30 3602/4885 |
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | LPL 1208/4885LIPG 785/4885USP30 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.